MDT-AP-3017
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 110.03999999999999
- os_event
- false
- age_years
- 5.9
- sex
- F
- new_clusters
- C4
- umap1_2d
- 5.117908737
- umap2_2d
- 5.019131347
- umap1_3d
- 2.295635021
- umap2_3d
- -0.729476294
- umap3_3d
- -2.627130142
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.380
- E2F_TARGETS+0.330
- SPERMATOGENESIS+0.240
- PANCREAS_BETA_CELLS+0.170
- PROTEIN_SECRETION+0.140
- HEDGEHOG_SIGNALING+0.120
- MYC_TARGETS_V1+0.120
- HEME_METABOLISM+0.080
- UV_RESPONSE_UP+0.070
- KRAS_SIGNALING_DN+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- NOTCH_SIGNALING-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- INTERFERON_GAMMA_RESPONSE-0.320
- MYC_TARGETS_V2-0.300
- ADIPOGENESIS-0.290
- ANGIOGENESIS-0.290
- OXIDATIVE_PHOSPHORYLATION-0.250
- APICAL_JUNCTION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475120 | — | — | 0.822 |
| 2 | TCGA-BA-A4IH-01A-11R-A266-07 | — | — | 0.815 |
| 3 | BS_3MYEMXPQ | medulloblastoma | — | 0.802 |
| 4 | BS_KN92S7YQ | medulloblastoma | — | 0.800 |
| 5 | SRR13780266 | — | cohortSC | 0.795 |
| 6 | MDT-AP-0210 | Med | Medulloblastoma | 0.793 |
| 7 | BS_5PJCHF6V | medulloblastoma | — | 0.792 |
| 8 | BS_HTEPAKCM | medulloblastoma | — | 0.789 |
| 9 | BS_A14Z8BBK | medulloblastoma | — | 0.785 |
| 10 | MDT-AP-2992 | Med | Medulloblastoma | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |